News

During the 40th Annual Chemotherapy Foundation Symposium, Sandra Kurtin, PhD, ANP-BC, FAPO, discussed improving health literacy in oncology care.

During the 40th Annual Chemotherapy Foundation Symposium®, Hope S. Rugo, MD, FASCO, outlined key priorities for the future of breast cancer research.

Immunotherapy has changed the face of cancer treatment, but requires appropriate irAE management to reach full potential.

Cemiplimab, in combination with platinum-based chemotherapy, has been approved for patients with advanced non–small cell lung cancer with no EGFR, ALK, or ROS1 aberrations.

Narjust Florez, MD, emphasizes why oncology health care professionals should bring a sense of urgency to ensuring that clinical trials represent all patient populations.

Celebrated reality star Teddi Mellencamp is using her Instagram as a platform to stress the importance of follow-up visits for patients with melanoma.

After demonstrating significant efficacy as a third-line treatment for patients with metastatic HER2-positive breast cancer, fam-trastuzumab deruxtecan-nxki has gained approval from the FDA for 5 indications and is under investigation across solid tumors.

Jesus Cepero, PhD, RN, highlights the value of holistic care environments in pediatric oncology.

Children with high-risk Hodgkin lymphoma were 10% less likely to relapse following treatment with brentuximab vedotin combination

A quality improvement project improved the time to molecular testing for patients with newly diagnosed, metastatic non–small cell lung cancer.

At a 5-year follow-up, the failure-free survival rate with capecitabine was 83.3% vs 72.2% with observation.

Kristin E. Rojas, M.D., FACS, FACOG, assistant professor of surgical oncology in the DeWitt Daughtry Department of Surgery and Sylvester Comprehensive Cancer Center at the University Miami Miller School of Medicine, realized she had struck a chord with women being treated for cancer when she started the Menopause Urogenital Sexual Health and Intimacy Clinic (MUSIC).

After 13.1 months of follow-up, the median progression-free survival in patients with EGFR-mutant non–small cell lung cancer who received a sintilimab-based regimen was 5.5 months.

During the International Kidney Cancer Symposium, Kiran Virdee, RN, BSN, CCRN-K, outlined best practices in kidney cancer symptom management.

Cobimetinib is now an FDA-approved therapy for patients with histiocytic neoplasms.

The rate of severe radiation dermatitis was reduced with the use of Mepital Film in patients with breast cancer undergoing mastectomy.

For caregivers providing emotional and physical care for cancer patients, can be a positive, rewarding experience that brings people closer together. On the other hand, caring for someone in need also brings forth various challenges that can contribute to mental health concerns.

Among 71 patients with neuroblastoma, 48.6% achieved an objective response and 29% achieved a complete response with a 4-drug combination.

Nancy Moldawer, RN, MSN, cochair of the Kidney Cancer Association's Clinical Advisory Board, speaks to unfolding data in the renal cell carcinoma space and the challenges in providing adjuvant therapy to this patient population.

Patients with HER2-positive breast cancer and brain metastases experienced a median progression-free survival of 8 months and a median overall survival of 14 months with HER2-targeted therapy.

It is imperative that nurses and other health care professionals not only recognize the disparities in preventive screenings but become part of the solution. Early detection and cancer treatment must be accessible for those with disabilities, as it can help save lives.

In this episode The Vitals, Jeannette Meyer, MSN, RN, CCRN-K, CCNS, PCCN-K, ACHPN, discusses the importance of advance directives in critical care and her work with homeless populations.

Approximately 19.2% of American adults are caregivers for individuals 18 years or older. An estimated 6% care for a loved one with cancer.

Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from October 2022.

Following CAR T-cell therapy, the onset of hypophosphatemia may represent a biomarker for immune effector cell–associated neurotoxicity syndrome incidence and severity.

Buying one for your practice or enhancing the one you have will help you cut costs and boost your financial stability.

A regimen of cediranib and olaparib improved radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer compared with olaparib monotherapy. However, the rate of dose reductions was doubled with the combination.

A presentation at the 2022 ESMO Congress found that xevinapant plus chemoradiotherapy decreased the risk of death by twice that of placebo for patients with unresectable, locally advanced head and neck squamous cell carcinoma.